PRGO vs XERS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRGO · Perrigo$15.94 ▼ 0.62%
XERS · Xeris Pharmaceuticals$16.97 ▲ 2.11%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRGO +34.4%
- XERS +141.1%
Head to head
| Metric | PRGO | XERS |
|---|---|---|
| Price | $15.94 | $16.97 |
| Change today | ▼ 0.62% | ▲ 2.11% |
| Market cap | $2.21B | $3.10B |
| Return, 3 months | +14.0% | +94.2% |
| Return, year to date | +22.6% | +116.2% |
| Return, 1 year | +35.0% | +148.5% |
| P/E (TTM) | – | – |
| P/B | 0.9 | 63.6 |
| P/E percentile vs own 5y | 87th | 0th |
| Dividend yield | 7.28% | – |
| Revenue growth (YoY, latest qtr) | -5.2% | +44.2% |
| Net profit growth (YoY) | -466.7% | +1,718.0% |
| Gross margin | 32.3% | 87.4% |
| Operating margin | 4.5% | 12.7% |
| Net margin | -43.3% | -1.8% |
| Return on equity | -51.4% | -27.1% |
| Analyst target vs. price | +19.2% | -2.8% |
| Analyst buy share | 100% | 83% |
| RSI (14) | 50 | 82 |
| 30-day volatility | 42.5% | 86.7% |
| Max drawdown, 1 year | -37.7% | -34.9% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- XERS is the largest of the group by market value.
- XERS has returned the most over the past year.
- XERS is growing revenue fastest.
- XERS keeps the most profit per dollar of sales.
- PRGO has been the calmest stock over the last 30 days.